Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, Oksanen M, Heiskanen R, Rouvinen-Lagerström N, Merisalo-Soikkeli M, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A. Bramante S, et al. Among authors: parviainen s. Int J Cancer. 2014 Aug 1;135(3):720-30. doi: 10.1002/ijc.28696. Epub 2014 Jan 10. Int J Cancer. 2014. PMID: 24374597
GMCSF-armed vaccinia virus induces an antitumor immune response.
Parviainen S, Ahonen M, Diaconu I, Kipar A, Siurala M, Vähä-Koskela M, Kanerva A, Cerullo V, Hemminki A. Parviainen S, et al. Int J Cancer. 2015 Mar 1;136(5):1065-72. doi: 10.1002/ijc.29068. Epub 2014 Jul 10. Int J Cancer. 2015. PMID: 25042001
Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.
Hirvinen M, Rajecki M, Kapanen M, Parviainen S, Rouvinen-Lagerström N, Diaconu I, Nokisalmi P, Tenhunen M, Hemminki A, Cerullo V. Hirvinen M, et al. Among authors: parviainen s. Hum Gene Ther. 2015 Mar;26(3):134-44. doi: 10.1089/hum.2014.069. Epub 2015 Feb 10. Hum Gene Ther. 2015. PMID: 25557131
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimäki A, Koski A, Liikanen I, Oksanen M, Nettelbeck DM, Kairemo K, Partanen K, Joensuu T, Kanerva A, Hemminki A. Hemminki O, et al. Among authors: parviainen s. Oncotarget. 2015 Feb 28;6(6):4467-81. doi: 10.18632/oncotarget.2901. Oncotarget. 2015. PMID: 25714011 Free PMC article. Clinical Trial.
70 results